Barriers in VTE Prevention: Impact on Therapeutic Choice and Duration Mary Ellen McCann, RN MA, National Blood Clot Alliance, Tarrytown, NY; Alan P. Brownstein, MPH, National Blood Clot Alliance, Tarrytown, NY Background

First Page		Document Content
Date: 2015-03-11 17:55:47 Blood Deep vein thrombosis Low molecular weight heparin Warfarin Pulmonary embolism Venous thrombosis Thrombosis Anticoagulant Aspirin Hematology Medicine Heparins		Barriers in VTE Prevention: Impact on Therapeutic Choice and Duration Mary Ellen McCann, RN MA, National Blood Clot Alliance, Tarrytown, NY; Alan P. Brownstein, MPH, National Blood Clot Alliance, Tarrytown, NY Background Add to Reading List Source URL: stoptheclot.org Download Document from Source Website File Size: 736,85 KB Share Document on Facebook

	A M E R I C A N S O C I E T Y O F DocID: 1qkK5 - View Document
	Case Report Journal of Orthopaedic Case Reports 2016 April - June: 6(2):PageThe Popliteal Vein Thrombosis in A Pediatric Patient: A Case Report. DocID: 1poyF - View Document
	SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Venous Thromboembolism (VTE) Prevention Following Surgery Pharmaceutical Services Department of Health and Community Serv DocID: 1p0MX - View Document
	April 21st, 2015 Kits for which Material Safety Data Sheets are not required The kits listed below are not labelled as hazardous. Considering the Regulation (EC) N° and the OSHA regulations 29 CFRg DocID: 1gtqX - View Document
	Global/integral assays in hemostasis diagnostics: promises, successes, problems and prospects DocID: 1g80I - View Document